1887
  1. Home
  2. Eurosurveillance
  3. Volume 31, Issue 2, 15/Jan/2026
  4. Article
Rapid communication Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

In Europe, the 2025/26 seasonal influenza epidemic started in October 2025. Co-circulation of A(H3N2) and A(H1N1)pdm09 was observed in several countries including France. We estimated early vaccine effectiveness (VE) against influenza virus in French outpatients (5,451 positives/18,816 negatives). A significant VE across all age groups was measured: 28% (95% CI: 17–37) for those aged ≥ 65 years, 45% (95% CI: 36–53) for 18–64-year-olds and 57% (95% CIs: 29–74) for 0–17-year-olds. Reinforcing vaccination uptake is warranted.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Closure
A corrected article has been published for this content:
Author’s correction for Euro Surveill. 2026;31(3)
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2026.31.2.2500992
2026-01-15
2026-02-07
/content/10.2807/1560-7917.ES.2026.31.2.2500992
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/31/2/eurosurv-31-2-2.html?itemId=/content/10.2807/1560-7917.ES.2026.31.2.2500992&mimeType=html&fmt=ahah

References

  1. European Centre for Disease Prevention and Control (ECDC) and World Health Organization Regional Office for Europe. (WHO/Europe). European Respiratory Virus Surveillance Summary (ERVISS). Stockholm: ECDC and Copenhagen: WHO/Europe; 2026. Available from: https://erviss.org/
  2. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13):30494.  https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494  PMID: 28382917 
  3. Kirsebom FC, Thompson C, Talts T, Kele B, Whitaker HJ, Andrews N, et al. Early influenza virus characterisation and vaccine effectiveness in England in autumn 2025, a period dominated by influenza A(H3N2) subclade K. Euro Surveill. 2025;30(46):2500854.  https://doi.org/10.2807/1560-7917.ES.2025.30.46.2500854  PMID: 41267661 
  4. Santé publique France (SPF). Infections respiratoires aiguës (grippe, bronchiolite, COVID-19). Bulletin du 24 décembre 2025. [Acute respiratory infections (influenza, bronchiolitis, COVID-19). Bulletin 24 December 2025]. Saint-Maurice: SPF; 24 Dec 2025. French. Available from: https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/infections-respiratoires-aigues-grippe-bronchiolite-covid-19-.-bulletin-du-24-decembre-2025
  5. Traore A, Charniga K, Grellet S, Terpant G, Da Cruz H, Lamy A, et al. Monitoring SARS-CoV-2 variants with complementary surveillance systems: risk evaluation of the Omicron JN.1 variant in France, August 2023 to January 2024. Euro Surveill. 2025;30(1):2400293.  https://doi.org/10.2807/1560-7917.ES.2025.30.1.2400293  PMID: 39790077 
  6. Blanquart F, Vieillefond V, Visseaux B, Abou Chakra CN, Nunes MC, Jacques A, et al. Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025. Euro Surveill. 2025;30(7):2500074.  https://doi.org/10.2807/1560-7917.ES.2025.30.7.2500074  PMID: 39980426 
  7. Clercq A, Blanquart F, Vieillefond V, Visseaux B, Chakra CNA, Nunes MC, et al. Influenza vaccine effectiveness and genetic diversity: insights from end-of-season community surveillance, France, 2024-2025. Emerg Microbes Infect. 2025;14(1):2562045.  https://doi.org/10.1080/22221751.2025.2562045  PMID: 40955037 
  8. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2025-2026 northern hemisphere influenza season. Geneva: WHO; 28 Feb 2025. Available from: https://cdn.who.int/media/docs/default-source/influenza/who-influenza-recommendations/vcm-northern-hemisphere-recommendation-2025-2026/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-northern-hemisphere-influenza-season.pdf?sfvrsn=857c2e9b_13&download=true
  9. Haute Autorité de Santé (HAS). Grippe saisonnière : la HAS précise la place des vaccins Efluelda et Fluad dans la stratégie vaccinale. [Seasonal influenza: the HAS clarifies the role of the Efluelda and Fluad vaccines in the vaccination strategy]. Saint-Denis: HAS; 9 May 2025. French. Available from: https://www.has-sante.fr/jcms/p_3604208/fr/grippe-saisonniere-la-has-precise-la-place-des-vaccins-efluelda-et-fluad-dans-la-strategie-vaccinale
  10. Eales O, McCaw JM, Shearer FM. Biases in routine influenza surveillance indicators used to monitor infection incidence and recommendations for improvement. Influenza Other Respir Viruses. 2024;18(12):e70050.  https://doi.org/10.1111/irv.70050  PMID: 39617738 
  11. Zambon M, Hayden FG. Influenza A(H3N2) subclade K virus: threat and response. JAMA. 2025.  https://doi.org/10.1001/jama.2025.25903  PMID: 41411120 
  12. Réseau Sentinelles (Sentinelles). Bulletin de surveillance épidémiologique pour la semaine 1 de l’année 2026, du 29/12/25 au 04/01/26. [ Epidemiological surveillance bulletin for week 1 of the year 2026, from 29/12/25 to 04/01/26]. Paris: Sentinelles; 7 Jan 2026. French. Available from: https://sentiweb.fr/
  13. Lipsitch M. Challenges of vaccine effectiveness and waning studies. Clin Infect Dis. 2019;68(10):1631-3.  https://doi.org/10.1093/cid/ciy773  PMID: 30204853 
  14. Ray GT, Lewis N, Klein NP, Daley MF, Lipsitch M, Fireman B. Depletion-of-susceptibles bias in analyses of intra-season waning of influenza vaccine effectiveness. Clin Infect Dis. 2020;70(7):1484-6.  https://doi.org/10.1093/cid/ciz706  PMID: 31351439 
  15. World Health Organization (WHO). Recommendations announced for influenza vaccine composition for the 2024-2025 northern hemisphere influenza season. Geneva: WHO; 23 Feb 2024. Available from: https://www.who.int/news/item/23-02-2024-recommendations-announced-for-influenza-vaccine-composition-for-the-2024-2025-northern-hemisphere-influenza-season
  16. World Health Organization (WHO). Recommendations announced for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 24 Feb 2023. Available from: https://www.who.int/news/item/24-02-2023-recommendations-announced-for-influenza-vaccine-composition-for-the-2023-2024-northern-hemisphere-influenza-season
  17. Kissling E, Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, et al. Influenza vaccine effectiveness in Europe and the birth cohort effect against influenza A(H1N1)pdm09: VEBIS primary care multicentre study, 2023/24. Euro Surveill. 2025;30(23):2500011.  https://doi.org/10.2807/1560-7917.ES.2025.30.23.2500011  PMID: 40511473 
  18. European Centre for Disease Prevention and Control (ECDC). Early estimates of seasonal influenza vaccine effectiveness against influenza requiring medical attention at primary care level in Europe, week 41 - 49, 2025. 2025. Stockholm: ECDC; 19 Dec 2025. Available from: https://www.ecdc.europa.eu/en/news-events/early-estimates-seasonal-influenza-vaccine-effectiveness-against-influenza-requiring
  19. Russ S, Nogareda F, Regan AK, Benedetti E, Pasinovich M, Voto C, et al. Interim effectiveness estimates of 2025 southern hemisphere influenza vaccines in preventing influenza-associated outpatient and hospitalized illness - eight southern hemisphere countries, March-September 2025. MMWR Morb Mortal Wkly Rep. 2025;74(36):570-8.  https://doi.org/10.15585/mmwr.mm7436a3  PMID: 40996960 
  20. Dapat C, Peck H, Jelley L, Diefenbach-Elstob T, Slater T, Hussain S, et al. Extended influenza seasons in Australia and New Zealand in 2025 due to the emergence of influenza A(H3N2) subclade K viruses. Euro Surveill. 2025;30(49):2500894.  https://doi.org/10.2807/1560-7917.ES.2025.30.49.2500894  PMID: 41383175 
  21. Abou Chakra CN, Blanquart F, Vieillefond V, Enouf V, Visseaux B, Haim-Boukobza S, et al. Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024. Emerg Microbes Infect. 2025;14(1):2466699.  https://doi.org/10.1080/22221751.2025.2466699  PMID: 40071892 
  22. Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, et al. Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026. N Engl J Med. 2025;393(22):2221-42.  https://doi.org/10.1056/NEJMsa2514268  PMID: 41160817 
Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Allan+De+Clercq&option1=author&noRedirect=true" class="nonDisambigAuthorLink">De Clercq Allan</a>, <a href="/search?value1=Fran%C3%A7ois+Blanquart&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Blanquart François</a>, <a href="/search?value1=Vincent+Vieillefond&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Vieillefond Vincent</a>, <a href="/search?value1=Benoit+Visseaux&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Visseaux Benoit</a>, <a href="/search?value1=Alexandra+Jacques&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Jacques Alexandra</a>, <a href="/search?value1=St%C3%A9phanie+Haim-Boukobza&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Haim-Boukobza Stéphanie</a>, <a href="/search?value1=Valentin+Wehrle&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Wehrle Valentin</a>, <a href="/search?value1=Guillaume+Deleglise&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Deleglise Guillaume</a>, <a href="/search?value1=Thomas+Duret&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Duret Thomas</a>, <a href="/search?value1=Sibylle+Bernard-Stoecklin&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bernard-Stoecklin Sibylle</a>, <a href="/search?value1=Danielle+Perez-Bercoff&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Perez-Bercoff Danielle</a>, <a href="/search?value1=Antoine+Oblette&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Oblette Antoine</a>, <a href="/search?value1=Bruno+Lina&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lina Bruno</a>, <a href="/search?value1=Marie+Anne+Rameix-Welti&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rameix-Welti Marie Anne</a>, <a href="/search?value1=Laurence+Josset&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Josset Laurence</a>, <a href="/search?value1=Vincent+Enouf&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Enouf Vincent</a>, <a href="/search?value1=Antonin+Bal&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bal Antonin</a>, <a href="/search?value1=on+behalf+of+the+RELAB+study+group&option1=author&noRedirect=true" class="nonDisambigAuthorLink">on behalf of the RELAB study group</a></span>. Interim vaccine effectiveness against influenza virus among outpatients, France, October 2025 to January 2026. <a href="/content/ecdc">Euro Surveill.</a> 2026;31(2):pii=2500992. <a href="https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500992" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2026.31.2.2500992</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 26 Dec 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 15 Jan 2026 </span> </p>
/content/10.2807/1560-7917.ES.2026.31.2.2500992
/content/10.2807/1560-7917.ES.2026.31.2.2500992
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error